| Sign In to gain access to subscriptions and/or personal tools. |
Mechanisms of action of mycophenolate mofetilSurroMed, Inc., Menlo Park, CA, USA Mycophenolate mofetil (MMF, CellCept®) is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5'-monophosphate dehydrogenase. MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation. MPA also inhibits the glycosylation and expression of adhesion molecules, and the recruitment of lymphocytes and monocytes into sites of inflammation. MPA depletes tetrahydrobiopterin and decreases the production of nitric oxide by inducible NO synthase without affecting the activity of constitutive NO synthases. Activated macrophages produce NO and superoxide, which combine to generate tissue-damaging peroxynitrite. By these two mechanisms MMF exerts anti-inflammatory activity. Unlike calcineurin inhibitors, MMF is not nephrotoxic and does not induce the production of TGFβ, which is fibrogenic. MMF does not increase blood pressure, cholesterol levels or triglyceride levels in recipients. MMF reduces acute and chronic rejection in allograft recipients and is efficacious in some nephropathies. Evidence is accumulating that MMF may have clinical utility in some autoimmune disorders. Lupus (2005) 14, s2-s8.
Key Words: antibodies • arthropathy • immunosuppressive • lymphocytes • monocytes • nephropathy
Lupus, Vol. 14, No. 1 suppl,
s2-s8 (2005) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
